Resistance to Targeted and Immunotherapies: What Happens Next - 09/20/22 скачать в хорошем качестве

Resistance to Targeted and Immunotherapies: What Happens Next - 09/20/22

Danielle Hicks, Chief Patient Officer for GO2 Foundation for Lung Cancer, and Dr. David Gandara, the Director of the Thoracic Oncology Program at UC Davis, discuss resistance to targeted therapies and immunotherapies. They explain what resistance is, and what the difference is between a true progression of disease versus an oligoprogression and pseudoprogression. They also discuss why a rebiopsy (or liquid biopsy) after progression is important. They talk in detail about the FLAURA, CHRYSALIS-2 and Teliso-V clinical trials, and targeted therapies ranging from erlotinib, osimertinib, amivantamab, mobocertinib, trastuzumab, and lazertinib. News on biomarkers such as T790M, MET, EGFR with exon 20 insertion and with exon 19 deletion among others is covered too. Overall, this is a highly detailed and technical conversation about resistance and progression that thoroughly covers the latest related findings and research in a number of clinical trials. Filmed on 9/20/22 and featuring David Gandara, MD - Professor Emeritus, Director, Thoracic Oncology Program, UC Davis